Sleeping Mask & Leave-On Treatment: Film Former, Occlusion & Overnight Active Delivery

Overview #

Sleeping masks sit in an awkward regulatory and formulation space that most brands don’t fully appreciate until they’re already in development. They’re not moisturizers. They’re not treatment serums. They’re a delivery architecture — a film-forming, occlusive matrix designed to hold actives against the skin for 6–8 hours while the consumer sleeps. Get the film former wrong and you either wake up with transfer on the pillowcase or a skin barrier that can’t breathe. Get the occlusion level wrong and you’ve either wasted your active payload or triggered milia in 30% of your consumer panel. This guide reflects how we actually evaluate and select formulation systems for sleeping mask briefs — the criteria we use, the thresholds we hold, and where most projects go sideways before they reach stability.

The Four Functional Layers You’re Actually Designing #

A sleeping mask brief usually arrives as “we want something rich, with retinol, that you leave on overnight.” That’s not a brief. That’s a wish list.

What we’re actually designing is four overlapping systems: (1) a film-forming network that creates the physical barrier, (2) an occlusive phase that controls transepidermal water loss (TEWL) reduction, (3) an active delivery matrix that determines how much of your hero ingredient actually reaches the stratum corneum, and (4) a sensory profile that determines whether the consumer actually uses it consistently.

All four have to work simultaneously. That’s the hard part.

Film formers in sleeping masks typically fall into three categories: synthetic polymers (carbomers, acrylates copolymers), natural polysaccharides (hyaluronic acid, konjac glucomannan, tremella extract), and silicone-based networks (dimethicone crosspolymers). Each creates a fundamentally different occlusion profile. Carbomer-based films are breathable and light — TEWL reduction in the 15–25% range. Petrolatum-anchored systems can push TEWL reduction above 60%, but that’s where the milia complaints start. In our lab, we target 30–45% TEWL reduction for most sleeping mask formats. That range delivers measurable hydration benefit without the occlusion-related congestion that kills repeat purchase.

The silicone crosspolymer route is interesting. Dimethicone/vinyl dimethicone crosspolymer at 2–4% gives a breathable, non-greasy film that consumers describe as “second skin.” It’s our default starting point for premium positioning. The problem is cost — it adds roughly $0.15–0.30 per unit at typical use levels, which matters when you’re trying to hit a $4.50 COGS target at MOQ 5,000.

Critical Selection Criteria and Numeric Thresholds #

This is where we push back on most briefs. Brand partners often want to select ingredients based on marketing story. We select based on performance thresholds — and if an ingredient can’t clear these, it doesn’t go in.

Criterion 1 — Film Integrity at 8 Hours
We measure film integrity by transfer resistance: a standardized fabric contact test at 8 hours post-application. Acceptable threshold is less than 5% active transfer to substrate. Most carbomer-only systems fail this at application weights above 1.5 g per application. We typically need a secondary film former — usually PVP or a hydroxyethylcellulose blend — to anchor the matrix.

Criterion 2 — pH Compatibility with Active Payload
This is usually where projects go sideways. Retinol is stable at pH 5.0–6.0. Vitamin C (L-ascorbic acid) needs pH below 3.5 for efficacy. Niacinamide works across pH 5.0–7.0 but converts to nicotinic acid above pH 7.0 and below pH 4.0. A sleeping mask trying to combine retinol and vitamin C in the same phase at a single pH is a formulation that doesn’t work — full stop. We’ve had three brand partners in the last two years insist on this combination. All three required reformulation after stability failure at week 6.

Criterion 3 — Preservative Efficacy Under Occlusion
Occlusive films create a warm, humid microenvironment on skin. That’s great for active delivery. It’s also a growth environment for gram-negative organisms if your preservative system isn’t robust. We run challenge testing per ISO Standards ISO 11930 on every sleeping mask batch. Our internal threshold: Category 2 pass (cosmetic criterion) with a minimum 2-log reduction of Pseudomonas aeruginosa at 28 days. Phenoxyethanol at 0.8–1.0% with ethylhexylglycerin at 0.3% is our most reliable system for this format. We’ve seen phenoxyethanol-only systems at 0.8% fail gram-negative challenge in occlusive formats — the film traps moisture and the preservative partitions into the water phase unevenly at scale.

Criterion 4 — Occlusion Index vs. Skin Type Target
We use a simple internal scoring matrix. Petrolatum and mineral oil score highest on occlusion (TEWL reduction 50–70%) but are incompatible with acne-prone positioning. Squalane and jojoba ester blends score in the 20–35% range — appropriate for combination skin. Ceramide-dominant systems with no heavy occlusive score 15–25% but deliver superior barrier repair signaling. The right occlusion level depends entirely on your target consumer. Honestly, most brands underestimate how much this single decision shapes the entire downstream formulation.

Criterion 5 — Active Permeation Under Film
This is the one criterion that almost never appears in brand briefs, and it should. An occlusive film can either enhance or block active permeation depending on the partition coefficient of the active and the film former chemistry. Hydrophilic actives (hyaluronic acid, niacinamide, panthenol) permeate well under most film systems. Lipophilic actives (retinol, bakuchiol, ceramides) require the film former to be partially lipophilic or you lose most of your payload to the film matrix itself. We’ve measured retinol skin delivery dropping by 40% when formulated in a high-MW carbomer network versus a silicone-crosspolymer base. That’s not a marginal difference.

Where Scale-Up Actually Breaks Things #

Lab success does not mean production success. This is the section most brand partners don’t want to hear, but it’s the most important one.

We had a sleeping mask project — a ceramide-niacinamide formula with a konjac glucomannan film system — that performed beautifully at 2 kg lab scale. Stable at 40°C/75% RH for 12 weeks. Sensory was exactly what the brand wanted. We scaled to 200 kg production batch. By week 8 of post-production stability, we had visible phase separation in 15% of units and a measurable drop in niacinamide content from 4.0% to 2.8%. The culprit was shear rate during the production-scale mixing step — the konjac network was partially degrading under high-shear homogenization, which changed the water activity in the continuous phase and destabilized the niacinamide-ceramide interaction. We now run a low-shear mixing protocol for polysaccharide-based film systems and require a 50 kg pilot batch before any full production run on novel film former combinations.

The fragrance load issue is real too. We’ve seen emulsion-type sleeping masks collapse at scale when fragrance load exceeds 0.8% — the fragrance components solubilize into the film former network and disrupt crosslinking. Most brands want 1.0–1.2% fragrance for sensory differentiation. That’s a conversation we have early.

Encapsulation is the other scale-up trap. Retinol encapsulation sounds like the obvious solution for overnight delivery — protect the active, control release, improve stability. And it works. But encapsulated retinol at 0.1% encapsulated (delivering roughly 0.05% free retinol equivalent) costs approximately 3× the raw material cost of unencapsulated retinol at the same nominal concentration. At MOQ 5,000 units, that’s a meaningful COGS impact. Most indie brands don’t price this in until we show them the BOM. For more on encapsulation economics and technology selection, see our encapsulation technology guide.

The Clinical Evidence That Actually Matters Here #

The most relevant head-to-head data for sleeping mask format versus standard leave-on moisturizer comes from a split-face, double-blind RCT (n=42, 8 weeks, published in the Journal of Cosmetic Dermatology) comparing an occlusive sleeping mask (petrolatum-based, 55% TEWL reduction) against a standard emollient cream (18% TEWL reduction) in subjects with mild-to-moderate xerosis. The sleeping mask arm showed 38% improvement in skin hydration (corneometry) versus 19% in the cream arm at week 8. Barrier function (TEWL measurement) improved 31% versus 14%. What the study doesn’t tell you — and what we’ve learned from our own batches — is that the petrolatum-level occlusion that drove those numbers is essentially incompatible with modern clean beauty positioning and creates real tolerability issues in non-xerotic skin types. The clinical win is real. The commercial application is narrow.

We’re still not fully convinced the evidence base for “active delivery enhancement” claims in sleeping masks is strong enough to support the marketing language most brands want. The mechanism is plausible — prolonged skin contact, occlusion-enhanced permeation, reduced evaporative loss of actives. But controlled data specifically on active delivery (not just hydration) in sleeping mask format is thin. We tell brand partners: you can claim the hydration and barrier benefit with confidence. The active delivery story is more of a positioning narrative than a clinically validated claim at this point.

For regulatory compliance on claim substantiation, we work within the framework of EU Cosmetics Regulation 1223/2009 and reference SCCS Scientific Opinion guidance on active ingredient safety assessments. For US market, FDA Cosmetics Guidelines govern claim boundaries — particularly relevant for any sleeping mask positioned with drug-adjacent language around “repair” or “treatment.”

Overnight Actives: What Works and What Doesn’t #

Retinol in sleeping masks is a natural fit — the prolonged contact time and occlusion-enhanced permeation genuinely improve delivery. We formulate retinol sleeping masks at 0.025–0.05% free retinol (or 0.1–0.3% encapsulated equivalent), pH 5.0–5.5, with a tocopherol antioxidant system at 0.2–0.5% to manage oxidative degradation. Packaging is non-negotiable: opaque, airless, or nitrogen-purged. We’ve rejected two packaging vendors in the past 18 months because their airless pump systems had oxygen ingress rates that failed our retinol stability threshold. For a deeper look at retinol system design, see our retinoid technology guide.

Peptides are well-suited to sleeping mask format. The prolonged contact time is genuinely beneficial for peptide permeation, and most peptides are stable across the pH 5.5–7.0 range that sleeping masks typically occupy. The issue is cost — signal peptides like Argireline (acetyl hexapeptide-3) or Matrixyl 3000 at efficacious concentrations (0.5–2.0% for most peptide complexes) add significant BOM cost. We almost always have a conversation about whether the peptide concentration in the brief is the actual efficacious dose or a label claim dose.

Niacinamide at 2–5% is probably the most reliable overnight active we formulate with. Stable, well-tolerated, compatible with most film systems, and the evidence base for brightening and barrier benefit is solid. The niacinamide-plus-retinol combination works well in sleeping mask format specifically because the prolonged contact time allows sequential delivery — retinol permeates first (lipophilic, faster membrane crossing), niacinamide follows in the aqueous phase.

Live probiotics in sleeping masks? We’ve stopped taking most of those briefs unless the brand is prepared for encapsulation costs and a realistic conversation about viable cell count at end of shelf life. Most aren’t. Postbiotics — ferment filtrates, lysates, cell wall fragments — deliver the microbiome-adjacent positioning without the stability nightmare. That’s where we steer most brands now.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a sleeping mask brief comes in — because the answers determine almost every formulation decision that follows.

If you’re targeting EU and making any “repair” or “treatment” language claims, we need to align on claim substantiation before we finalize the active payload. If you’re targeting the US mass market with a sub-$25 retail price point, the encapsulated retinol story probably doesn’t survive the COGS math. If you’re targeting sensitive skin, your occlusion index ceiling is around 35% and your preservative system needs to be as minimal as possible — which creates real challenge test risk that we need to plan around.

Here’s what we need in your brief to give you an accurate formulation proposal and timeline:

What to Include in Your Brief:
1. Target market(s) and retail price point — this sets the COGS ceiling and determines which actives are commercially viable
2. Skin type target (dry/normal/combination/acne-prone) — determines occlusion index range and film former selection
3. Hero active(s) with desired on-pack concentration — we’ll tell you if the concentration is stable and deliverable in this format
4. Claim priorities (hydration, brightening, anti-aging, barrier repair) — determines which clinical endpoints we design toward
5. Packaging preference or constraint — airless vs. jar vs. tube changes the preservative and oxidation-sensitive active strategy entirely
6. Fragrance preference and load — anything above 0.8% triggers a reformulation conversation
7. Regulatory markets and any known restricted ingredient list — especially relevant if you have a clean beauty positioning or EU/NMPA dual registration requirement; for NMPA requirements see NMPA Cosmetic Regulation

The more of these you answer upfront, the faster we move. We’ve had projects stall for six weeks because the brand couldn’t decide between jar and airless packaging — and that single decision changed the preservative system, the retinol concentration, and the BOM cost.

Frequently Asked Questions #

Q: We want to call it a “sleeping mask” but it’s basically a rich night cream — does the format matter for registration?
In most markets, the format name is a marketing descriptor, not a regulatory category. What matters is the finished product’s intended use claim and ingredient list. That said, in China under NMPA Cosmetic Regulation, “mask” products (面膜) have specific registration pathways and some ingredient restrictions that don’t apply to moisturizers — so if you’re registering in China, the format name absolutely matters and we need to know upfront.

Q: Can we put 0.1% retinol in a sleeping mask and keep it stable?
0.1% free retinol in a sleeping mask is at the edge of what we’d call reliably stable. In our experience, 0.05% free retinol in an optimized antioxidant system (tocopherol 0.3%, BHT 0.02%, nitrogen-purged airless packaging) passes 12-month accelerated stability. At 0.1%, we see oxidative degradation in roughly 3 out of 5 projects by month 9 unless we move to encapsulation. We’d recommend either dropping to 0.05% free retinol or switching to encapsulated retinol at 0.2–0.3% for the 0.1% equivalent claim.

Q: Our brand is clean beauty — can we avoid phenoxyethanol in a sleeping mask?
Yes, but it’s harder than in a rinse-off format. The occlusive film creates a challenging preservation environment. We’ve had success with a combination of ethylhexylglycerin at 0.5%, caprylyl glycol at 0.3%, and levulinic acid at 0.2% — but this system requires a water activity below 0.85 and a pH between 4.5 and 5.5 to pass ISO 11930 Category 2. If your formula drifts outside that pH window, the system fails. It’s not a perfect solution.

Q: How long does overnight active delivery actually work — does the skin absorb everything in the first hour?
Honestly, the absorption kinetics depend heavily on the active and the film system. For most hydrophilic actives, the majority of permeation happens in the first 2–3 hours. The occlusive film’s main job after that is preventing TEWL and keeping the skin surface hydrated — which indirectly supports continued permeation. For lipophilic actives in a well-designed film system, we see more sustained delivery across 6–8 hours. The “all night delivery” claim is more defensible for lipophilic actives than hydrophilic ones.

Q: What’s the minimum MOQ for a sleeping mask with a custom active blend?
For a standard emulsion-type sleeping mask with off-the-shelf actives, our minimum is 1,000 units. For a formula with encapsulated actives, custom peptide blends, or novel film former combinations, we require a 50 kg pilot batch (approximately 2,000–3,000 units depending on fill weight) before committing to full production. The pilot batch is not optional for complex formulas — it’s how we catch the scale-up failures before they become your inventory problem.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.